reviewNature MedicineMar 1, 2023Closed access

Challenges and opportunities in NASH drug development

SAStephen A. HarrisonAMAlina M. AllenJDJulie DubourgMNMazen NoureddinNANaim Alkhouri

University of Oxford · Mayo Clinic in Arizona · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

337
total citations
FWCI
70.79
Percentile
100%
References
125
Citations per year

Authors

5

Topics & keywords

Topics
Keywords
  • Drug development
  • Clinical trial
  • Nonalcoholic steatohepatitis
  • Medicine
  • Intensive care medicine
  • Nonalcoholic fatty liver disease
  • Drug
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.